STRATA Skin Sciences Reports Landmark Clinical Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- Clinical Trial Results: STRATA's 308-nm excimer laser combined with oral JAK inhibitors achieved an overall response rate of 85.5% in 188 children, significantly surpassing the control group's 53.8%, indicating the therapy's substantial clinical value in treating pediatric progressive vitiligo.
- Safety and Efficacy: Throughout the 48-week treatment period, all adverse events were mild to moderate and fully resolved, with no cases of tuberculosis or hepatitis observed, showcasing the favorable safety profile that enhances the therapy's marketability.
- Intellectual Property Strategy: STRATA is expanding its patent portfolio to support market exclusivity for combination therapies involving its excimer laser and JAK inhibitors, aiming to enter new clinical indications and strengthen its competitive position in dermatological treatments.
- Insurance Coverage Expansion: The American Medical Association's approval of updated reimbursement codes is expected to triple patient coverage starting in 2027, improving treatment economics and further driving STRATA's market growth.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
